Acetaminophen-Opioid Combination Global Market Report 2025

The acetaminophen-opioid combination market size has grown strongly in recent years. It will grow from $3.02 billion in 2024 to $3.18 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. Growth during the historic period can be attributed to the rising prevalence of moderate to severe pain conditions, increased reliance on combination analgesics, a growing number of surgical procedures, an expanding geriatric population, and the development of pharmaceutical sales infrastructure in emerging markets.

The acetaminophen-opioid combination market size is expected to see strong growth in the next few years. It will grow to $3.88 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. Growth in the forecast period can be attributed to increasing awareness of multimodal pain management, rising demand for non-invasive and oral pain therapies, a growing emphasis on personalized medicine and customized pain treatments, increased investment in abuse-deterrent formulations (ADF), and the global rise in cancer and orthopedic disorders. Key trends expected during this period include progress in ADF technologies, integration of electronic health records (EHR) with prescription monitoring programs (PMPs), adoption of technology-enabled remote pain management tools, innovations in extended-release drug delivery systems, and advancements in pharmacogenomics and personalized treatment approaches.

The increasing prevalence of chronic pain is expected to drive the growth of the acetaminophen-opioid combination market in the coming years. Chronic pain is defined as persistent or recurring pain lasting longer than three to six months, extending beyond the typical recovery period, and often significantly impacting an individual’s daily life and well-being. This rise is largely due to sedentary lifestyles, which lead to poor posture and weakened muscles, placing additional strain on the body and contributing to long-term pain. Acetaminophen-opioid combinations offer effective relief by simultaneously addressing multiple pain pathways, improving pain management, enhancing daily functionality, and potentially reducing the required opioid dosage. For example, in June 2024, the Australian Institute of Health and Welfare reported that chronic conditions in 2023 led Australians to lose around 4.4 million years of healthy life, representing 85% of the nation's total disease burden. As a result, the growing incidence of chronic pain is fueling the expansion of the acetaminophen-opioid combination market.

The rising number of orthopedic surgical procedures is expected to drive the growth of the acetaminophen-opioid combination market in the coming years. Orthopedic surgeries involve procedures that diagnose, treat, or repair conditions affecting the bones, joints, muscles, and ligaments of the musculoskeletal system. The demand for these surgeries is increasing as the aging population faces more degenerative musculoskeletal disorders, leading to a greater need for interventions that restore mobility and reduce pain. Acetaminophen-opioid combinations are effective in managing moderate to severe postoperative pain following orthopedic surgeries by targeting multiple pain pathways. This approach improves patient comfort and mobility while potentially reducing the need for higher opioid dosages. For example, in September 2023, Curvo Labs, Inc., a US-based healthcare technology firm, reported that the number of knee replacement surgeries in the U.S. rose from 1,235,835 in 2021 to 1,299,084 in 2022. Thus, the growing number of orthopedic surgical procedures is fueling the expansion of the acetaminophen-opioid combination market.

Major companies in the acetaminophen-opioid combination market are concentrating on developing advanced products, such as oxycodone hydrochloride and acetaminophen tablets, to improve pain relief effectiveness while minimizing the risk of opioid dependence. These tablets combine a potent opioid analgesic with a non-opioid pain reliever to address moderate to severe pain through dual-action mechanisms that work via complementary pathways. For example, in May 2025, Elite Pharmaceuticals, Inc., a US-based specialty pharmaceutical company, introduced its generic version of Percocet in 5mg/325mg, 7.5mg/325mg, and 10mg/325mg strengths. Manufactured under current Good Manufacturing Practice (cGMP) standards, this product offers a reliable, high-quality alternative to branded Percocet and addresses immediate-release pain management needs. It is approved for the treatment of moderate to moderately severe pain and represents a notable entry for Elite into the targeted generic pharmaceutical market.

Major players in the acetaminophen-opioid combination market are Bayer AG, Abbott Laboratories, GlaxoSmithKline plc (GSK), Sun Pharmaceutical Industries Ltd, Endo Pharmaceuticals, Amneal Pharmaceuticals, Mallinckrodt Pharmaceuticals plc, Lupin Pharmaceuticals, Granules Pharmaceuticals Inc., Alvogen, Camber Pharmaceuticals Inc., Watson Laboratories, Genus Lifesciences Inc., Elite Pharmaceuticals Inc., Healthkind Labs Pvt Ltd, Eraas International, Boca Pharmacal Inc., Taj Life Sciences Pvt. Ltd., West-Ward Pharmaceuticals Corp., Divine savior pvt. ltd.

North America was the largest region in the acetaminophen-opioid combination market in 2024. The regions covered in acetaminophen-opioid combination report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acetaminophen-opioid combination market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

An acetaminophen-opioid combination is a prescribed medication that combines acetaminophen, a non-opioid analgesic and antipyretic, with an opioid pain reliever to provide enhanced pain management. Its use is strictly regulated due to potential risks, including opioid dependency and liver toxicity associated with high doses of acetaminophen.

The primary types of acetaminophen-opioid combinations include hydrocodone-acetaminophen, oxycodone-acetaminophen, codeine-acetaminophen, tramadol-acetaminophen, and others. Hydrocodone-acetaminophen is a prescription medication used for severe pain that merges an opioid and non-opioid component, with risks such as addiction, liver damage, and respiratory depression. It is offered in various formulations, including low-dose, moderate- to high-dose, and extended-release combinations, for multiple indications like acute and chronic pain. These products are distributed through several channels, including hospital pharmacies, retail pharmacies, online pharmacies, and clinics.

The acetaminophen-opioid combinations market research report is one of a series of new reports that provides acetaminophen-opioid combinations market statistics, including the acetaminophen-opioid combinations industry global market size, regional shares, competitors with the acetaminophen-opioid combinations market share, detailed acetaminophen-opioid combinations market segments, market trends, opportunities, and any further data you may need to thrive in the acetaminophen-opioid combinations industry. This acetaminophen-opioid combinations market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The acetaminophen-opioid combination market consists of sales of pentazocine and acetaminophen, meperidine and acetaminophen and tapentadol and acetaminophen. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.